Their past shelf filings has been reasonable. Last was mid last year? They sell the shares really fast - I mean like 1 week or so (not sure if my memory is correct). They will need to raise money this year to get the NDA completed, Manufacturing/distribution systems and World Wide Sales force going etc. They will probably shelf about 20 million shares later this year, Probably after the NDA is submitted (guessing)? .
OK if they are honest about it...who is to blame for the delay= Not realizing they still need to prepare the QA manufacturing systems, Uli, Davis, Mills, BOD (excluding Soland). That is one long Perp Walk.
They have 100M, but an extra 50M can be raised. Total now is 150M, agree. You mention 250M, I think you mean 225M(...common stock from 150,000,000 to 225,000,000.) ..I should have said " authorized ", not reserved. So if we vote in the increase to 225M, we still have our OS of 100M, but the company will be authorized to self list an addition 125M. Is that correct. TIA
If the increase #3 on the Proxy List is voted in, will they then have 225 M TOTAL SHARES which includes the 100M OS? So 225M - 100M = 125 M in Reserve? ie, TOTAL SHARES =100M OS/FLOAT plus 125M in RESERVE = 225M.
Well 3 for sure. 6? I still need to read it more thoroughly. I am not sure though if I am counting the shares correctly. 2 ways I am thinking is
A) there are 100Million OS/Float. So if they are saying they have 150M and want to increase them is it 150M -100M = 50 in reserve now not counted in the OS/Float total. And after the increase we still have the 100M OS/Float, but in reserve we will have 125M (225M -100M=125M in Reserve) ? OR
B) is it 100M OS/Float and 150M already in reserve. So if they vote in the increase it will be 100M OS/Float Plus 225M in reserve? HELP Somebody !!!
I went over the Proxy ...fast, skipped a ton of junk. But here's my first impression of the above points :
1)Election of three Class II directors, Stephen R. Biggar, M.D., Ph.D., Torsten Rasmussen and Daniel Soland, to hold office until our 2018 Annual Meeting of Stockholders;--- This seems like a No Brainer, unless you want to hold Biggar & Rasmussen somewhat responsible for not figuring out we were not going to meet the Manufacturing QA system for the NDA. Mr Soland has my vote.
2) I am not exactly clear about this issue- a little help here. TIA.
3) Shares Outstanding:100.17M. So this increase ( if I am not mistaken and I very well could be) if voted in means this increase does not go into the Float until needed. They are held in reserve. So help me out here, they must have 50million shares in reserve now since they have 150M now and want to raise it another 75M shares. So the reserve shares will increase to 125M shares. Yes , no? Again just thinking this increase hinders a hostile take over, will allow Acadia to raise money fast for R&D and Manufacturing & sales force in the USA and in the EU. BTW I think the other thing they can do is expand the Pipeline, buy another company or drug rights. Of course Bonus shares if you want to keep your key people too. ( I'm key person too ;) )
4) Isn't this just Bonus shares/money? What else ?
5) Vote in Ernst & Young LLP- its a No Brainer.
6) Is this a Q&A session for shareholders or what other business? Because I really, really, I mean really want to know why the F they told us they were on track with the NDA ( Let it go Crecy) when they full well knew they were not. And why, if they lied should they keep their job. I don't foresee getting any answers. Any one thinking about going to San Diego?
ACADIA PHARMACEUTICALS INC.
3611 Valley Centre Drive, Suite 300
San Diego, California 92130
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 15, 2015
You are cordially invited to attend the 2015 Annual Meeting of Stockholders of ACADIA Pharmaceuticals Inc., a Delaware corporation (“ACADIA” or the “Company”). The meeting will be held on June 15, 2015 at 8:00 a.m. local time at the offices of Cooley LLP , 4401 Eastgate Mall, San Diego, California 92121 for the following purposes:
1. To elect three Class II directors named herein to hold office until the Company’s 2018 Annual Meeting of Stockholders.
2. To approve an amendment to the Company’s 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.
3. To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 225,000,000.
4. To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement.
5. To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
6. To conduct any other business properly brought before the meeting.
These items of business are more fully described in the proxy statement accompanying this notice.
The record date for the annual meeting is April 16, 2015. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment or postponement thereof.
Important Notice Regarding the Availability of Proxy Materials for the Stockholders’ Meeting to Be Held
on June 15, 2015 at 8:00 a.m. local time at the offices of Cooley LLP ,
4401 Eastgate Mall, San Diego, California 92121
Geez large print...tiny print...paper paper paper ....Holly ...Looks like the main issue will be PROPOSAL 3
APPROVALOF INCREASEINTHE NUMBEROF SHARESOF AUTHORIZED STOCK
The Board of Directors is requesting stockholder approval of an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of our common stock from 150,000,000 shares to 225,000,000 shares.
Wow they must be expecting some good news if they want to do that. Now a while back I mentioned Acadia would have to increase their share number, so I am not surprised. Also what they have to do is expand their PIPELINE. ie buy a company or rights to other drugs. Both cost money to make money. Also, Increasing shares will hinder a hostile take over if I am not mistaken.
1) boosting 2) Unsubstantiated posts 3) Screaming 4) Silent Covering. Right now you are number 2. (pu)-IGNORED.
I would bet Acadia will be meeting with a few candidates next week. CEO could be announced before end of April. Really, I mean how long could it take?
"" Evolocumab cut CV events in half vs. statin therapy "", 53%, OSLER study granted by AMGN.
Yeah I kinda remember this, I think this is the article that brought ACAD to my attention. I bought in at about $12. I really can't remember and don't care that much at this point, I could have bought at 7 and a day or so later it jumped to 12+.
So, how does all of this information translate into value for shareholders?
As an investor, I am supremely confident in this model, and the numbers/data that has been supported. I think conservative estimates are being used, and with those estimates I see no way that pima does not become one of the best-selling drugs of all time, assuming there are no colossal mishaps on behalf of management.
But for the sake of argument, the model predicts peak global sales of $20.45 billion -- the five key points above suggest that sales could be even greater - but I am applying a whopping 50% discount rate to allow for human error. This means that we can cut peak penetration of pima in half from the already low psychosis percentage of patients that was being used. Hence, peak global sales become $10 billion.
If we look at other companies with single (assumed) blockbuster products such as Pharmacyclics or Alexion Pharmaceuticals (NASDAQ:ALXN), then three times peak sales valuation is far from being pricey. Thus, a market cap of $30 billion or a target price over $300 is not unrealistic. Right now you may be thinking that I am "psychotic," but when Pharmacyclics was a $100 million company or Alexion was a $700 million company, no one thought either would reach their current valuations. In fact, last year, not many thought Pharmacyclics would reach a $9 billion market cap, but it did with the rising of estimates.
The bottom line is that as time passes, expect estimates to rise quickly for pima, which will then drive the valuation for Acadia. The current market potential for pima simply does not reflect the valuation of the PDP indication let alone ADP and Schizo.
Veterans' Diseases Associated with Agent Orange
Man with a diabetes kit
VA assumes that certain diseases can be related to a Veteran's qualifying military service. We call these "presumptive diseases."
VA has recognized certain cancers and other health problems as presumptive diseases associated with exposure to Agent Orange or other herbicides during military service. Veterans and their survivors may be eligible for benefits for these diseases.
A rare disease caused when an abnormal protein, amyloid, enters tissues or organs
Chronic B-cell Leukemias
A type of cancer which affects white blood cells
Chloracne (or similar acneform disease)
A skin condition that occurs soon after exposure to chemicals and looks like common forms of acne seen in teenagers. Under VA's rating regulations, it must be at least 10 percent disabling within one year of exposure to herbicides.
Diabetes Mellitus Type 2
A disease characterized by high blood sugar levels resulting from the body’s inability to respond properly to the hormone insulin
A malignant lymphoma (cancer) characterized by progressive enlargement of the lymph nodes, liver, and spleen, and by progressive anemia
Ischemic Heart Disease
A disease characterized by a reduced supply of blood to the heart, that leads to chest pain
A cancer of plasma cells, a type of white blood cell in bone marrow
A group of cancers that affect the lymph glands and other lymphatic tissue
A progressive disorder of the nervous system that affects muscle movement
Peripheral Neuropathy, Early-Onset
A nervous system condition that causes numbness, tingling, and motor weakness. Under VA's rating regulations, it must be at least 10 percent disabling within one year of herbicide exposure.
Porphyria Cutanea Tarda
A disorder characterized by liver dysfunction and by thinning and blistering of the skin in sun-exposed areas. Under VA's rating regulations, it must be at
The Department of Veterans Affairs established a service-connection for Vietnam veterans suffering from Parkinson's disease, ischemic heart disease (IHD) and B-cell leukemias such as hairy-cell leukemia. These illnesses are now considered "presumed" illnesses. This "presumption" simplifies and speeds up the application process for VA benefits. It is important to note that this new policy will not go into effect until sometime in 2010. At which point affected veterans will be urged to submit new disability claims. Additional information about Agent Orange and VA's services and programs for veterans exposed to the chemical are available at VA's Agent Orange webpage, or call the toll-free helpline at 800-749-8387.
In plan English, if you have been diagnosed with Heart Disease and you served "in" Vietnam. You should contact your local veteran service officer and file a claim with the Veterans Benefits Administration.
Type Value Conf.
resist. 45.88 2
resist. 39.96 2
supp 38.26 5
supp 37.28 2
supp 36.38 4
supp 35.12 7
supp 32.98 2
supp 30.98 2
supp 30.40 4
supp 28.88 4
supp 28.21 2
supp 26.57 2
Support now moderately stronger than the weaker Resistance at 39.96 .
This price target of $48 is somewhat short term. When the NDA gets submitted before the end of the yr, followed by approval in 2016 if not sooner- that Price target could easily double. And since the FDA has already reviewed the P3 data with a thumbs up. I think Pima has at least a 90+% chance of being approved quickly by the FDA.